Mark Alan Rosen1, Ganesh Adluru1, Ravi Amaravadi2, Yiqun Xue1, Yu Jiangsheng1, Hee-Kwon Song1, Naomi Haas2, Peter O'Dwyer2
1Radiology, University of Pennsylvania, Philadelphia, PA, United States; 2Medicine, University of Pennsylvania, Philadelphia, PA, United States
DCE-MRI using large-volume radial imaging was used to gauge response of metastatic prostate cancer to combination therapy including the anti-angiogenic agent, sorafenib. We observed strong anti-vascular response of tumors to a seven-day course of sorafenib. This effect was reversed on follow-up DCE-MRI at day 21, after a mandated three-day sorafenib free-interval, suggesting that the sorafenib effects on tumor were rapidly reversible. We also noted that alterations in tumor vascularity, as reflected in changes in tumor AUC60, were negatively correlated with early changes in serum PSA levels, in concert with clinical results revealing sorafenibs potential to increase PSA levels.